Zobrazeno 1 - 10 of 47 pro vyhledávání: '"Ommen HB"'
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
Autor: Othman J; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.; Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia., Potter N; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom., Ivey A; Alfred Hospital and Monash University, Melbourne, VIC, Australia., Tazi Y; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Papaemmanuil E; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY., Jovanovic J; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom., Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Gilkes A; Department of Haematology, Cardiff University, Cardiff, United Kingdom., Gale R; Department of Haematology, University College London Cancer Institute, London, United Kingdom., Rapoz-D'Silva T; Department of Haematology, University College London Cancer Institute, London, United Kingdom., Runglall M; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Kleeman M; Genomics Facility, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Dhami P; Genomics Facility, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Thomas I; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom., Johnson S; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom., Canham J; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom., Cavenagh J; St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom., Kottaridis P; University College London Hospital NHS Foundation Trust, London, United Kingdom., Arnold C; Clinical Haematology, Belfast City Hospital, Belfast, United Kingdom., Ommen HB; Department of Haematology, University Hospital, Aarhus, Denmark., Overgaard UM; Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark., Dennis M; The Christie NHS Foundation Trust, Manchester, United Kingdom., Burnett A; Paul O'Gorman Leukaemia Centre, Glasgow University, Glasgow, Scotland., Wilhelm-Benartzi C; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom., Huntly B; Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Russell NH; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Dillon R; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Publikováno v: Blood [Blood] 2024 Aug 15; Vol. 144 (7), pp. 714-728.
Zobrazit plný text záznamu
4
Akademický článek
Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma.
Autor: Holst JM; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus., Pedersen MB; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus., Enemark MB; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus., Hansen MC; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Hematology, Odense University Hospital, Odense., Noerhave PR; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus., Plesner TL; Department of Pathology, Rigshospitalet, Copenhagen., Frederiksen H; Department of Hematology, Odense University Hospital, Odense., Moeller MB; Department of Pathology, Odense University Hospital, Odense., Hamilton-Dutoit SJ; Department of Pathology, Aarhus University Hospital, Aarhus., Noergaard P; Department of Pathology, Herlev Hospital, Copenhagen., Mortensen BK; Department of Hematology, Herlev Hospital, Herlev., Ommen HB; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus., Stentoft J; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus., Tam W; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York City., Ludvigsen M; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus., Chan WC; Department of Pathology, City of Hope Medical Center, Duarte., Birkbak NJ; Department of Molecular Medicine, Aarhus University Hospital, Aarhus., Inghirami G; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York City., D'Amore F; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus. frandamo@rm.dk.
Publikováno v: Haematologica [Haematologica] 2024 Jul 25. Date of Electronic Publication: 2024 Jul 25.
Zobrazit plný text záznamu
5
Akademický článek
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Autor: Othman J; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.; Faculty of Medicine and Health, University of Sydney, Sydney, Australia., Potter N; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom., Ivey A; Alfred Hospital and Monash University, Melbourne, Australia., Jovanovic J; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom., Runglall M; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Gilkes A; Department of Haematology, Cardiff University, Cardiff, United Kingdom., Thomas I; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom., Johnson S; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom., Canham J; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom., Cavenagh J; Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom., Kottaridis P; Department of Haematology, University College London Hospital NHS Foundation Trust, London, United Kingdom., Arnold C; Clinical Haematology, Belfast City Hospital, Belfast, United Kingdom., Ommen HB; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark., Overgaard UM; Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark., Dennis M; The Christie NHS Foundation Trust, Manchester, United Kingdom., Burnett A; Paul O'Gorman Leukaemia Centre, Glasgow University, Glasgow, United Kingdom., Wilhelm-Benartzi C; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom., Dillon R; Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom., Russell NH; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Publikováno v: Blood [Blood] 2024 May 09; Vol. 143 (19), pp. 1931-1936.
Zobrazit plný text záznamu
6
Akademický článek
Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
Autor: Gronlund JK; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark., Veigaard C; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark., Juhl-Christensen C; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark., Skou AS; Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark., Melsvik D; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark., Ommen HB; Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.
Publikováno v: European journal of haematology [Eur J Haematol] 2024 Apr; Vol. 112 (4), pp. 601-610. Date of Electronic Publication: 2024 Jan 10.
Zobrazit plný text záznamu
7
Akademický článek
Autor: Andersen N; Hæmatologisk Afdeling, Odense Universitetshospital.; Forskningsenheden for Hæmatologi, Syddansk Universitet., Al-Mashadi AL; Hæmatologisk Afdeling, Aalborg Universitetshospital., Rotbain EHC; Afdeling for Blodsygdomme, Københavns Universitetshospital - Rigshospitalet., Kristensen IB; Hæmatologisk Afdeling, Odense Universitetshospital.; Forskningsenheden for Hæmatologi, Syddansk Universitet., Lauritsen TB; Blodsygdomme, Aarhus Universitetshospital., Poulsen CB; Hæmatologisk Afdeling, Sjællands Universitetshospital, Roskilde., Ommen HB; Blodsygdomme, Aarhus Universitetshospital., Andersen CBL; Afdeling for Blodsygdomme, Københavns Universitetshospital - Rigshospitalet., El-Galaly TC; Hæmatologisk Afdeling, Odense Universitetshospital.; Forskningsenheden for Hæmatologi, Syddansk Universitet.; Hæmatologisk Afdeling, Aalborg Universitetshospital., Abildgaard N; Hæmatologisk Afdeling, Odense Universitetshospital.; Forskningsenheden for Hæmatologi, Syddansk Universitet.; Forskningsenhed for AgeCare, Academy of Geriatric Cancer Research, Odense Universitetshospital.
Publikováno v: Ugeskrift for laeger [Ugeskr Laeger] 2024 Jan 22; Vol. 186 (4). Date of Electronic Publication: 2024 Jan 22.
Zobrazit plný text záznamu
8
Akademický článek
Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma.
Autor: Bønløkke ST; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Fenger-Eriksen C; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Anesthesiology, Aarhus University Hospital, Aarhus, Denmark., Ommen HB; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Hvas AM; Faculty of Health, Aarhus University, Aarhus, Denmark.
Publikováno v: Blood advances [Blood Adv] 2023 Nov 28; Vol. 7 (22), pp. 7056-7066.
Zobrazit plný text záznamu
9
Akademický článek
Prophylaxis with low dose tranexamic acid in acute myeloid leukemia patients undergoing intensive chemotherapy.
Autor: Bønløkke ST; Department of Clinical Biochemistry Aarhus University Hospital Aarhus N Denmark.; Department of Clinical Medicine Aarhus University Aarhus Denmark., Severinsen MT; Department of Hematology, Clinical Cancer Research Centre Aalborg University Hospital Aalborg Denmark.; Department of Clinical Medicine Aalborg University Aalborg Denmark., Ommen HB; Department of Hematology Aarhus University Hospital Aarhus Denmark.; Department of Clinical Medicine Aarhus University Aarhus Denmark., Eriksen CF; Department of Anesthesiology Aarhus University Hospital Aarhus Denmark.; Department of Clinical Medicine Aarhus University Aarhus Denmark., Hvas AM; Department of Clinical Medicine Aarhus University Aarhus Denmark.
Publikováno v: EJHaem [EJHaem] 2023 May 05; Vol. 4 (3), pp. 690-694. Date of Electronic Publication: 2023 May 05 (Print Publication: 2023).
Zobrazit plný text záznamu
10
Akademický článek
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
Autor: Dillon R; Department of Medical and Molecular Genetics, King's College London, London, UK. richard.dillon@kcl.ac.uk.; Department of Clinical Haematology, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, UK. richard.dillon@kcl.ac.uk., Maycock S; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Jackson A; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Fox S; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Freeman S; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.; Centre for Clinical Haematology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Craddock C; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.; Centre for Clinical Haematology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Thomas C; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Homer E; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Leahy J; Blood Cancer UK, London, UK., Mamwell A; Blood Cancer UK, London, UK., Potter N; Department of Medical and Molecular Genetics, King's College London, London, UK., Russell N; School of Medicine, Clinical Sciences Building, The University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK., Wei A; Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne. VIC 3000, Australia., Ommen HB; Department of Hematology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus C, Denmark., Hemmaway C; Department of Haematology, Auckland City Hospital, Auckland, New Zealand., Knapper S; Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK., Billingham L; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Publikováno v: BMC cancer [BMC Cancer] 2022 Nov 14; Vol. 22 (1), pp. 1174. Date of Electronic Publication: 2022 Nov 14.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje